In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: Role of CYP2C19 and flavin-containing monooxygenase 3

Drug Metabolism and Disposition

Volumn 38, Issue 1, 2010, Pages 25-31

  Yanni, Souzan B ^a   Annaert, Pieter P ^c   Augustijns, Patrick ^c   Ibrahim, Joseph G ^b   Benjamin Jr , Daniel K ^d   Thakker, Dhiren R ^a  

^a University of North Carolina   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^c DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DIMETHYLANILINE MONOOXYGENASE; FLAVIN CONTAINING MONOOXYGENASE 3; OXIDE; UNCLASSIFIED DRUG; VORICONAZOLE;

ADULT; AEROBIC METABOLISM; ARTICLE; CHILD; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; ENZYME INHIBITION; FROZEN SECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER METABOLISM; LIVER MICROSOME; METABOLITE; PLASMA CLEARANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD;

ADULT; AGING; ANTIFUNGAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; BIOCATALYSIS; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; KINETICS; LIVER; MICROSOMES, LIVER; MIDDLE AGED; MODELS, BIOLOGICAL; OXYGENASES; PYRIMIDINES; TRIAZOLES; YOUNG ADULT;

EID: 73149102760     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.029769     Document Type: Article

References (23)

1. Alcorn J and McNamara PJ (2008) Using ontogeny information to build predictive models for drug elimination. Drug Discov Today 13:507-512.
2. Björkman S (2004) Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol 59:691-704.
3. Björkman S (2006) Prediction of cytochrome P450-mediated hepatic drug clearance in neonates, infants and children: how accurate are available scaling methods? Clin Pharmacokinet 45: 1-11.
4. Chen N, Aleksa K, Woodland C, Rieder M, and Koren G (2006) Ontogeny of drug elimination by the human kidney. Pediatr Nephrol 21:160-168.
5. Edginton AN, Schmitt W, Voith B, and Willmann S (2006) A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet 45:683-704.
6. Filler G, Bendrick-Peart J, and Christians U (2008) Pharmacokinetics of mycophenolate mofetil and sirolimus in children. Ther Drug Monit 30:138-142.
7. Hines RN and McCarver DG (2002) The ontogeny of human drug-metabolizing enzymes: phase 1 oxidative enzymes. J Pharmacol Exp Ther 300:355-360.
8. Hyland R, Jones BC, and Smith DA (2003) Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 31:540-547.
9. Johnson TN, Rostami-Hodjegan A, and Tucker GT (2006) Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 45: 931-956.
10. Karlsson MO, Lutsar I, and Milligan PA (2009) Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 53:935-944.
11. Kennedy M (2008) Hormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence. Clin Pharmacol Ther 84:662-673.
12. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, and Kauffman RE (2003) Developmental pharmacology - drug disposition, action, and therapy in infants and children. New Engl J Med 349:1157-1167.
13. Levêque D, Nivoix Y, Jehl F, and Herbrecht R (2006) Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 27:274-284.
14. Litalien C, Théorêt Y, and Faure C (2005) Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet 44:441-466.
15. Murayama N, Imai N, Nakane T, Shimizu M, and Yamazaki H (2007) Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol 73:2020-2026.
16. Obach RS and Reed-Hagen AE (2002) Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab Dispos 30:831-837.
17. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, and Kleinermans D (2002) Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 46:2546-2553.
18. Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman AN, Smith DA, Walker DK, and Wood N (2003) The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 31:731-741.
19. Shimada T, Tsumura F, and Yamazaki H (1999) Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos 27:1274-1280.
20. Steinbach WJ and Benjamin DK (2005) New antifungal agents under development in children and neonates. Curr Opin Infect Dis 18:484-489.
21. Theuretzbacher U, Ihle F, and Derendorf H (2006) Pharmacokinetic/ pharmacodynamic profile of voriconazole. Clin Pharmacokinet 45:649-663.
22. Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, et al. (2004) Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 48:2166-2172.
23. Yanni SB, Annaert PP, Augustijns P, Bridges A, Gao Y, Benjamin DK Jr, and Thakker DR (2008) Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes. Drug Metab Dispos 36:1119-1125.